Daptomycin

O=C(N[C@H](CC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(NCC(N[C@H](C(N[C@@](C(N[C@@H](C(N[C@H]1CC(O)=O)=O)C)=O)([H])CC(O)=O)=O)CCCN)=O)=O)[C@H](OC([C@](NC([C@](NC([C@@](NC(CNC1=O)=O)([H])CO)=O)([H])[C@H](C)CC(O)=O)=O)([H])CC(C(C=CC=C2)=C2N)=O)=O)C)=O)=O)[C@@H](NC(CCCCCCCCC)=O)CC3=CNC4=CC=CC=C34

[1]Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20 (2) :191-6.|[2]Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31 (8) :1199-203.|[3]Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31 (7) :1093-9.